SIGA stock surges premarket on FDA approval for intravenous version of smallpox drug

May 19, 2022 9:07 AM ETSIGA Technologies, Inc. (SIGA)By: Anuron Mitra, SA News Editor

Financial stock market graph. Selective focus.

Diego Thomazini/iStock via Getty Images

  • Shares of SIGA Technologies (NASDAQ:SIGA) jumped 21.7% to $8.99 in Thursday premarket trading, after the company got U.S. Food and Drug Administration (FDA) approval for the intravenous (IV) formulation of its TPOXX treatment for smallpox.
  • "The IV formulation is an important option for those who are unable to swallow the oral capsules of TPOXX," SIGA said in a statement.
  • SIGA's oral formulation of TPOXX is approved in the U.S., Canada and Europe for the treatment of smallpox.
  • Last week, SIGA bagged a U.S. Department of Defense contract to supply up to ~$7.5M of oral TPOXX.
  • Up to Wednesday's close, SIGA stock -1.7% YTD.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.